MacroGenics (MGNX) Q2 2025 earnings summary

Executive summary

• Focused on developing antibody-based cancer therapeutics, with three proprietary candidates in clinical development and three FDA-approved products partnered or out-licensed.

• Strategic collaborations with global biopharma have provided over $1.6 billion in non-dilutive funding since inception.

• Newly appointed President and CEO Eric Risser outlined strategic priorities for 2025 and 2026, focusing on pipeline advancement and capital efficiency.

• Received $70 million upfront from Sagard Healthcare Partners for a royalty purchase agreement on ZYNYZⓇ.

• Operates a commercial-scale cGMP antibody manufacturing facility, also providing contract manufacturing services.

Financial highlights

• Total revenue for Q2 2025 was $22.2M, up 106% year-over-year, driven by higher contract manufacturing and collaboration revenue.

• Net loss for Q2 2025 was $36.3M, improved from $55.7M in Q2 2024.

• R&D expenses decreased to $40.8M from $51.7M year-over-year, mainly due to discontinued programs and lower development costs.

• SG&A expenses dropped to $9.3M from $14.4M, reflecting lower stock-based compensation and reduced professional fees.

• Cost of manufacturing services increased to $8.9M from $2.6M, reflecting higher CDMO client volume.

Outlook and guidance

• Cash, equivalents, and marketable securities, plus anticipated partner payments and cost savings, expected to fund operations through H1 2027.

• Ongoing cost-saving measures are being implemented to extend financial runway while progressing the pipeline.

• Clinical updates for lorigerlimab and expansion of ADC programs are anticipated in the second half of 2025.